The Discovery of Antiangiogenic Molecules: A Historical Review

Author(s): Domenico Ribatti

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 4 , 2009

Become EABM
Become Reviewer
Call for Editor


In a landmark publication of 1971, Folkman proposed antiangiogenesis as a potential target in cancer biology [1]. Over the past 30 years most research on tumor angiogenesis has been aimed at inhibiting the process of tumorinduced vessel formation. The first angiogenesis inhibitor, bevacizumab, was approved by the Food and Drug Administration in 2004 for the treatment of metastatic carcinoma of the colon-rectum. Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials.

Keywords: Angiogenesis, antiangiogenesis, history of medicine, tumor growth

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Published on: 01 March, 2012
Page: [345 - 352]
Pages: 8
DOI: 10.2174/138161209787315855
Price: $65

Article Metrics

PDF: 13